HIGHLIGHTS
- who: Parva Bhatt et al. from the Tufts University Medical Center, Boston, MA, USA have published the research: Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse, in the Journal: (JOURNAL)
- what: Patients in this study had received a median of two prior lines of therapy, with 54% of patients having received prior Bortezomib as part of front-line therapy . Patients in this study demonstrated deep and durable responses with approximately 39% of patients achieving a CR or better and 26.7% achieving MRD negativity .
- future . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.